Paul Fonteyne has been a director since October 2019. Mr. Fonteyne is the retired chairman and CEO of Boehringer-Ingelheim (BI) USA. He was with Boehringer-Ingelheim for 15 years in leadership roles both in the U.S. and globally. During this time, he led teams that grew BI’s sales and earnings several fold in the U.S. and participated in acquisitions and divestitures that led to a significantly greater focus of BI’s portfolio of companies in the U.S. in two main segments of Animal Health and Human Pharmaceuticals. During his more than 30 years in the pharmaceutical industry, Paul also held commercial leadership roles at Merck & Co. Inc. for nine years, and Abbott Laboratories for eight years. Mr. Fonteyne serves on the Board of Directors of several clinical-stage biotechnology companies including Gelesis, DalCor (Chairman), ResTorbio inc. (Chair of compensation Committee), and Ypsomed AG, a device company. He has also served on the Board of PhRMA and chaired the National Pharmaceutical Council and served as Chair of the American Cancer Society CEOs Against Cancer. In addition, Mr. Fonteyne serves as an Executive in Residence to Canaan Partners, a Venture Capital Fund dedicated to early stage venture investing in healthcare and technology where he advises several companies in the Canaan portfolio. Mr. Fonteyne holds an M.S. in Chemical Engineering from the University of Brussels and an MBA for Carnegie Mellon University.
As of November, 2020 AMAG Pharmaceuticals, Inc. is now a subsidiary of the Covis Pharma Group. For more information about Covis, please visit (covispharma.com)
